Ipswich Investment Management Co. Inc. Has $115,000 Stake in Vaccitech plc (NASDAQ:VACC)

Ipswich Investment Management Co. Inc. decreased its stake in shares of Vaccitech plc (NASDAQ:VACC) by 14.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 23,075 shares of the company’s stock after selling 4,000 shares during the quarter. Ipswich Investment Management Co. Inc.’s holdings in Vaccitech were worth $115,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of VACC. Baird Financial Group Inc. acquired a new stake in shares of Vaccitech during the 4th quarter worth approximately $217,000. Renaissance Technologies LLC lifted its holdings in shares of Vaccitech by 198.2% in the 2nd quarter. Renaissance Technologies LLC now owns 34,000 shares of the company’s stock worth $70,000 after purchasing an additional 22,600 shares in the last quarter. Janney Montgomery Scott LLC bought a new position in shares of Vaccitech in the 3rd quarter worth $46,000. Citadel Advisors LLC bought a new position in shares of Vaccitech in the 2nd quarter worth $31,000. Finally, Millennium Management LLC lifted its holdings in shares of Vaccitech by 32.8% in the 4th quarter. Millennium Management LLC now owns 40,388 shares of the company’s stock worth $97,000 after purchasing an additional 9,967 shares in the last quarter. Institutional investors and hedge funds own 26.13% of the company’s stock.

Vaccitech Trading Down 7.4 %

Shares of VACC traded down $0.20 during trading hours on Friday, reaching $2.51. The stock had a trading volume of 3,441 shares, compared to its average volume of 244,643. Vaccitech plc has a 12 month low of $1.64 and a 12 month high of $5.10. The firm has a 50-day simple moving average of $2.75 and a 200 day simple moving average of $3.13. The company has a market capitalization of $96.75 million, a price-to-earnings ratio of -1.76 and a beta of -0.40.

About Vaccitech

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer.